Letter to the Editor regarding the article "Prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: A meta-analysis".
作者信息
Yang Tingfang, Wang Li, Zhang Yong
机构信息
Department of Radiation Oncology, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Department of Pathology, The First People's Hospital of Yunnan, Province, Kunming, China.
出版信息
Crit Rev Oncol Hematol. 2021 Jun;162:103295. doi: 10.1016/j.critrevonc.2021.103295. Epub 2021 May 13.
Abstract
摘要
相似文献
1
Letter to the Editor regarding the article "Prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: A meta-analysis".致编辑的信：关于文章《骨髓增生异常综合征患者中SF3B1突变的预后意义：一项荟萃分析》
Crit Rev Oncol Hematol. 2021 Jun;162:103295. doi: 10.1016/j.critrevonc.2021.103295. Epub 2021 May 13.
2
Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.SF3B1 突变在骨髓增生异常综合征中的预后价值和临床特征：一项荟萃分析。
Crit Rev Oncol Hematol. 2019 Jan;133:74-83. doi: 10.1016/j.critrevonc.2018.07.013. Epub 2018 Aug 3.
3
Prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: A meta-analysis.SF3B1 突变对骨髓增生异常综合征患者预后的意义：一项荟萃分析。
Crit Rev Oncol Hematol. 2020 Jan;145:102832. doi: 10.1016/j.critrevonc.2019.102832. Epub 2019 Nov 15.
4
Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes.国际工作组关于SF3B1突变型骨髓增生异常综合征提议的验证
Blood. 2021 Sep 16;138(11):989-992. doi: 10.1182/blood.2021010831.
5
Significance of SF3B1 Mutations in Myeloid Neoplasms.SF3B1 突变在髓系肿瘤中的意义。
Clin Lab Med. 2023 Dec;43(4):597-606. doi: 10.1016/j.cll.2023.07.005. Epub 2023 Sep 4.
6
-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity.- 突变型骨髓增生异常综合征/骨髓增殖性肿瘤：一种独特的分子和预后实体。
Haematologica. 2022 May 1;107(5):1189-1192. doi: 10.3324/haematol.2021.280463.
7
[Significance of somatic mutations on the prognosis of myelodysplastic syndromes].[体细胞突变对骨髓增生异常综合征预后的意义]
Rinsho Ketsueki. 2018;59(8):1078-1085. doi: 10.11406/rinketsu.59.1078.
8
Validation of the WHO 2016 proposals for Myelodysplastic syndromes patients with the presence of ring sideroblasts but without excess blasts.世界卫生组织2016年关于伴有环形铁粒幼细胞但无原始细胞增多的骨髓增生异常综合征患者提议的验证。
Br J Haematol. 2017 Sep;178(5):813-816. doi: 10.1111/bjh.14168. Epub 2016 Jun 13.
9
The Molecular Pathology of Myelodysplastic Syndrome.骨髓增生异常综合征的分子病理学。
Pathobiology. 2019;86(1):24-29. doi: 10.1159/000488712. Epub 2018 May 23.
10
Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations.伴有 SF3B1 突变的髓系疾病的病理谱和分子特征。
Am J Clin Pathol. 2021 Sep 8;156(4):679-690. doi: 10.1093/ajcp/aqab010.
Zotero 插件